Skip to main content

Table 3 Efficacy Study 2. Summary of protection based on clinical and laboratory results

From: Efficacy of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine in cattle using a direct contact transmission model

Treatment Group   Percent Protection from Outcomes Percent Positive for Antibodies to FMDV NSPs
N Clinical FMD (1–15 dpcc) FMDV or FMDV RNA in plasma (0–7, 9 dpcc) FMDV RNA in oronasal fluid (0, 2, 4 dpcc) FMDV RNA in probang (27, 34, 41 dpcc) FMDV in probang (27, 34, 41 dpcc)
T1: IDL challenged seeder steers 10 0% ND ND ND ND ND
T2: 1o AdtA24 5 × 1010 PU vaccinated; Intermingled with 10 IDL challenged ‘seeder steers’ for 2–3 days 12 100%
No oronasal lesions
100% 0% 18% 27% 9%a - 0 dpcc
91% -30 dpcc
T3: 1o naïve; Intermingled with 10 IDL challenged ‘seeder steers’ for 2–3 days 6 0% 0% 0% 17% 17% 0% - 0 dpcc
100%-30 dpcc
T4: 2o AdtA24 5 × 1010 PU vaccinated; Intermingled with 6 T2: 1o vaccinated and exposed steers
(Room 1)
4 100%
No oronasal lesions
100% 100% 100% 100% 0% - 0 and 30 dpcc
T5: 2o naïve; Intermingled with 6 T2: 1o vaccinated and exposed steers
(Room 2)
4 100%
No oronasal lesions
100% 75% 50% 100% 0% - 0 and 30 dpcc
T6: 2o naïve; Intermingled with 6 T3: 1o naïve and exposed steers (Room 3) 4 0% 0% 0% 25% 25% 0% - 0 dpcc
100%-30 dpcc
  1. Dpcc days post contact challenge, NSP nonstructural protein, 1o primary, 2o secondary, IDL intradermolingual challenge, PU particle units
  2. aone false positive (consistent with reported diagnostic specificity rates for this assay [36, 37])